Wolfgang Miesbach

TL;DR: Nonanticoagulant properties such as the reduction in interleukin 6 release have been shown to improve the complex picture of coagulopathy in patients with COVID-19, and adapted to the individual risk of thrombosis and the d-dimer value, higher doses can be considered.

TL;DR: A single infusion of AMT-060 had a positive safety profile and resulted in stable and clinically important increases in FIX activity, a marked reduction in spontaneous bleeds and FIX concentrate use, without detectable cellular immune responses against capsids.

TL;DR: A monoclonal antibody targeting tissue factor pathway inhibitor (TFPI) that can be administered subcutaneously (s.c.) has the potential to alter current concepts of prophylaxis in hemophilia.

TL;DR: Presenting FVIII and inhibitor concentration are potentially useful to tailor IST in AHA and are associated with a lower rate of complete remission and decreased survival.

TL;DR: Vitamin D deficiency is common among APS patients and is associated with clinically defined thrombotic events, and in vitro vitamin D inhibited the expression of TF induced by anti-β2GPI-antibodies.